As of 2024-12-15, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -7.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 1,336.88 mil USD. NRIX's TTM EBITDA according to its financial statements is -185.00 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (37.78) - (39.08) | (37.91) |
| Upside | -286.4% - -292.8% | -287.0% |
| Date | EV/EBITDA |
| 2024-12-13 | -7.22 |
| 2024-12-12 | -7.34 |
| 2024-12-11 | -7.62 |
| 2024-12-10 | -7.91 |
| 2024-12-09 | -7.38 |
| 2024-12-06 | -7.65 |
| 2024-12-05 | -7.15 |
| 2024-12-04 | -7.44 |
| 2024-12-03 | -7.46 |
| 2024-12-02 | -7.69 |
| 2024-11-29 | -7.93 |
| 2024-11-27 | -7.59 |
| 2024-11-26 | -7.81 |
| 2024-11-25 | -7.82 |
| 2024-11-22 | -7.91 |
| 2024-11-21 | -8.03 |
| 2024-11-20 | -8.13 |
| 2024-11-19 | -8.19 |
| 2024-11-18 | -7.81 |
| 2024-11-15 | -8.24 |
| 2024-11-14 | -9.75 |
| 2024-11-13 | -9.86 |
| 2024-11-12 | -9.81 |
| 2024-11-11 | -10.24 |
| 2024-11-08 | -9.93 |
| 2024-11-07 | -9.90 |
| 2024-11-06 | -9.80 |
| 2024-11-05 | -9.20 |
| 2024-11-04 | -9.05 |
| 2024-11-01 | -8.83 |
| 2024-10-31 | -8.88 |
| 2024-10-30 | -8.68 |
| 2024-10-29 | -9.11 |
| 2024-10-28 | -9.59 |
| 2024-10-25 | -9.52 |
| 2024-10-24 | -9.12 |
| 2024-10-23 | -8.95 |
| 2024-10-22 | -9.24 |
| 2024-10-21 | -9.22 |
| 2024-10-18 | -9.06 |
| 2024-10-17 | -8.93 |
| 2024-10-16 | -9.35 |
| 2024-10-15 | -8.99 |
| 2024-10-14 | -9.10 |
| 2024-10-11 | -8.51 |
| 2024-10-10 | -7.84 |
| 2024-10-09 | -7.88 |
| 2024-10-08 | -7.89 |
| 2024-10-07 | -7.71 |
| 2024-10-04 | -7.97 |